Hepatitis C virus (HCV) infection is a serious health problem worldwide that can lead to hepatocellular carcinoma or end-stage liver disease. Current treatment with pegylated interferon, ribavirin, and NS3/4A protease inhibitor would lead to a good prognosis in a large population of patients, but there is still no effective vaccine for HCV. HCV robustly infects hepatocytes in the liver. However, extrahepatic manifestations such as mixed cryoglobulinemia, a systemic immune complex-mediated disorder characterized by B-cell proliferation, which may evolve into overt B-cell non-Hodgkin's lymphoma, have been demonstrated. HCV-RNA is often found to be associated with peripheral blood lymphocytes, suggesting a possible interaction with peripheral blood mononuclear cells (PBMCs), especially B-cells with HCV. B-cell HCV infection was a matter of debate for a long time, and the new advance in HCV in vitro infectious systems suggest that exosome can transmit HCV genome to support “infection.” We aimed to clarify the susceptibility of primary B-cells to HCV infection, and to study its functional effect. In this article, we found that the recombinant HCV J6JFH1 strain could infect human B-cells isolated from the peripheral blood of normal volunteers by the detection of both HCV-negative-strand RNA by reverse transcription polymerase chain reaction, and NS5A protein. We also show the blocking of HCV replication by type I interferon after B-cell HCV infection. Although HCV replication in B-lymphocytes showed lower efficiency, in comparison with hepatocyte line (Huh7) cells, our results clearly demonstrate that human B-lymphocytes without other non-B-cells can actually be infected with HCV, and that this interaction leads to the induction of B-cells' innate immune response, and change the response of these cells to apoptosis.
Get full access to this article
View all access options for this article.
References
1.
AgnelloV, ChungRT, and KaplanLM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med, 1992; 327:1490–1495.
2.
AizakiH, MorikawaK, FukasawaM, et al. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol, 2008; 82:5715–5724.
3.
AlyHH, OshiumiH, ShimeH, et al. Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). PLoS One, 2011; 6:e21284.
4.
AlyHH, QiY, AtsuzawaK, et al. Strain-dependent viral dynamics and virus–cell interactions in a novel in vitro system supporting the life cycle of blood-borne hepatitis C virus. Hepatology, 2009; 50:689–696.
5.
AlyHH, ShimotohnoK, HijikataM, and SeyaT. In vitro models for analysis of the hepatitis C virus life cycle. Microbiol Immunol, 2012; 56:1–9.
6.
AsselahT, and MarcellinP. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int, 2014; 34:60–68.
7.
BareP, MassudI, ParodiC, et al. Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J Gen Virol, 2005; 86:1717–1727.
8.
BartoschB, DubuissonJ, and CossetFL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med, 2003; 197; 633–642.
9.
BartoschB, VitelliA, GranierC, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem, 2003; 278:41624–41630.
10.
CastetV, FournierC, SoulierA, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol, 2002; 76:8189–8199.
11.
ChenZ, ZhuY, RenY, et al. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLoS One, 2011; 6:e18933.
12.
DonadaC, CrucittiA, DonadonV, et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat, 1998; 5:179–185.
13.
EbiharaT, ShingaiM, MatsumotoM, WakitaT, and SeyaT. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology, 2008; 48:48–58.
14.
EvansMJ, von HahnT, TscherneDM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature, 2007; 446:801–805.
15.
FerriC, CaraccioloF, ZignegoAL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol, 1994; 88:392–394.
16.
FrangeulL, MussetL, CrestaP, CacoubP, HurauxJM, and LunelF. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol, 1996; 25:427–432.
17.
FriedMW, ButiM, DoreGJ, et al. Once-daily simeprevir (TMC435) with Pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR Study. Hepatology, 2013; 58:1918–1929.
18.
HarwoodNE, and BatistaFD. New insights into the early molecular events underlying B cell activation. Immunity, 2008; 28:609–619.
19.
HsuM, ZhangJ, FlintM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A, 2003; 100:7271–7276.
20.
InokuchiM, ItoT, UchikoshiM, et al. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol, 2009; 627:619–627.
21.
ItoM, MasumiA, MochidaK, et al. Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection. J Innate Immun, 2010; 2:607–617.
22.
JacobsonIM, McHutchisonJG, DusheikoG, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med, 2011; 364:2405–2416.
23.
JahanS, KhaliqS, SiddiqiMH, et al. Anti-apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virol J, 2011; 8:522.
24.
KambaraH, FukuharaT, ShiokawaM, et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol, 2012; 86:1382–1393.
25.
KaravattathayyilSJ, KalkeriG, LiuHJ, et al. Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma. Am J Clin Pathol, 2000; 113:391–398.
26.
KasamaY, SekiguchiS, SaitoM, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood, 2010; 116; 4926–4933.
27.
KondoY, and ShimosegawaT. Direct effects of hepatitis C virus on the lymphoid cells. World J Gastroenterol, 2013; 19:7889–7895.
28.
LaduS, CalvisiDF, ConnerEA, FarinaM, FactorVM, and ThorgeirssonSS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology, 2008; 135:1322–1332.
29.
LanfordRE, ChavezD, ChisariFV, and SureauC. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol, 1995; 69:8079–8083.
30.
LaskusT, RadkowskiM, WangLF, VargasH, and RakelaJ. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis, 1998; 178:1189–1192.
31.
LeratH, BerbyF, TrabaudMA, et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest, 1996; 97:845–851.
32.
LokAS, GardinerDF, HézodeC, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatrol, 2014; 60:490–499.
33.
LoweSW, and LinAW. Apoptosis in cancer. Carcinogenesis, 2000; 21:485–495.
34.
MacParlandSA, PhamTN, GuyCS, and MichalakTI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology, 2009; 49:1431–1441.
35.
MarukianS, JonesCT, AndrusL, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology, 2008; 48:1843–1850.
36.
MazzaroC, FranzinF, TulissiP, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer, 1996; 77:2604–2613.
37.
McKeatingJA, ZhangLQ, LogvinoffC, et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol, 2004; 78:8496–8505.
38.
MizuochiT, ItoM, TakaiK, and YamaguchiK. Peripheral blood memory B cells are resistant to apoptosis in chronic hepatitis C patients. Virus Res, 2011; 155:349–351.
39.
MurakamiK, KimuraT, ShojiI, et al. Virological characterization of the hepatitis C virus JFH-1 strain in lymphocytic cell lines. J Gen Virol, 2008; 89:1587–1592.
40.
MuratoriL, GibelliniD, LenziM, et al. Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood, 1996; 88:2768–2774.
41.
PhanT, BeranRKF, PetersC, LorenzIC, and LindenbachBD. Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol, 2009; 83:8379–8395.
42.
PileriP, UematsuY, CampagnoliS, et al. Binding of hepatitis C virus to CD81. Science, 1998; 282:938–941.
43.
PlossA, EvansMJ, GaysinskayaVA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature, 2009; 457:882–886.
44.
QuJ, ZhangQ, LiY, et al. The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol, 2012; 13:15.
45.
RadkowskiM, Gallegos-OrozcoJF, JablonskaJ, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology, 2005; 41:106–114.
46.
RamakrishnaiahV, ThumannC, FofanaI, et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A, 2013; 110:13109–13113.
47.
SarhanMA, PhamTNQ, ChenAY, and MichalakTI. Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol, 2012; 86:3723–3735.
48.
SchmidtWN, StapletonJT, LaBrecqueDR, et al. Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV RNA concentrations and correlation with liver histology. Hepatology, 2000; 31:737–744.
49.
Schulze-BergkamenH, KrammerP.H. Apoptosis in cancer—implications for therapy. Semin Oncol, 2004; 31:90–119.
50.
SetoWK, LaiCL, FungJ, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol, 2010; 53:444–448.
51.
SungVM, ShimodairaS, DoughtyAL, et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol, 2003; 77:2134–2146.
52.
TurnerNC. Hepatitis C and B-cell lymphoma. Ann Oncol, 2003; 14:1341–1345.
53.
WakitaT, PietschmannT, KatoT, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med, 2005; 11:791–796.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
